Approaches to Antifungal Therapies and Their Effectiveness among Patients with Cryptococcosis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The goal of this study was to determine the degree to which the persistence of cryptococcosis, overall 1-year mortality, and 1-year mortality due to cryptococcosis were influenced by initial antifungal treatment regimen in a cohort of adults with cryptococcosis treated at a tertiary care medical center. Risk factors, underlying conditions, treatment, and mortality information were obtained for 204 adults with cryptococcosis from Duke University Medical Center (DUMC) from 1996 to 2009. Adjusted risk ratios (RR) for persistence and hazard ratios (HR) for mortality were estimated for each exposure. The all-cause mortality rate among patients with nonsevere disease (20%) was similar to that in the group with disease (26%). However, the rate of cryptococcosis-attributable mortality with nonsevere disease (5%) was much lower than with severe disease (20%). Flucytosine exposure was associated with a lower overall mortality rate (HR, 0.4; 95% confidence interval [CI], 0.2 to 0.9) and attributable mortality rate (HR, 0.5; 95% CI, 0.2 to 1.2). Receiving a nonrecommended antifungal regimen was associated with a higher relative risk of persistent infection at 4 weeks (RR, 1.9; 95% CI, 0.9 to 4.3), and the rate of attributable mortality among those not receiving the recommended dose of initial therapy was higher than that of those receiving recommended dosing (HR, 2.3; 95% CI, 1.0 to 5.0). Thus, the 2010 Infectious Diseases Society of America (IDSA) guidelines are supported by this retrospective review as a best-practice protocol for cryptococcal management. Future investigations should consider highlighting the distinction between all-cause mortality and attributable mortality so as not to overestimate the true effect of cryptococcosis on patient death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Self-citationCalculating measures of biological interaction
Andersson, T., Alfredsson, L., Källberg, H., Zdravkovic, S., & Ahlbom, A. (2005) · European Journal of Epidemiology · doi:10.1007/s10654-005-7835-x · Cited by 1,498
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study
Dromer, F., Mathoulin-Pélissier, S., Launay, O., Lortholary, O., & the French Cryptococcosis Study Group (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040021 · Cited by 374
McCarthy, K. M., Morgan, J., Wannemuehler, K. A., Mirza, S. A., Gould, S. M., Mhlongo, N., Moeng, P., Maloba, B. R., Crewe-Brown, H. H., Brandt, M. E., et al. (2006) · AIDS · doi:10.1097/qad.0b013e3280106d6a · Cited by 115
Cited by
Maziarz, E. K., & Perfect, J. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.006 · Cited by 698
Self-citationAntifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593
“In resource-rich regions with access to amphotericin B and 5-flucytosine, the 1-year mortality owing to cryptococcosis is approximately 25% (Bratton et al. 2013), whereas in resource-limited regions where fluconazole is the only available therapy the mortality is much higher (Sloan et al.”
BackgroundChang, C. C., Harrison, T. S., Bicanic, T. A., Chayakulkeeree, M., Sorrell, T. C., Warris, A., Hagen, F., Spec, A., Oladele, R., Govender, N. P., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00731-4 · Cited by 326
Self-citationIn Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
Self-citationA Call to Arms: Quest for a Cryptococcal Vaccine
Caballero Van Dyke, M. C., & Wormley, F. L. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.002 · Cited by 61
“Additionally, patients who are HIV negative or are not organ transplant recipients may be among the most at risk groups for mortality attributed to cryptococcosis in resourceavailable settings; perhaps because of delayed diagnosis due to lack of clinical suspicion and the myriad of other underlying diseases that are p…”
Background
Metadata
- Authors
- Bratton, E. W., El Husseini, N., Chastain, C. A., Lee, M. S., Poole, C., Stürmer, T., Weber, D. J., Juliano, J. J., & Perfect, J. R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-06
- Volume
- 57
- Issue
- 6
- Pages
- 2485-2495
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2072886771
- Cited by
- 42
- References
- 5
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Approaches to Antifungal Therapies and Their Effectiveness among Patients with Cryptococcosis. https://app.cochat.ai/papers/10.1128/aac.01800-12
- The paper
- Bratton, E. W., El Husseini, N., Chastain, C. A., Lee, M. S., Poole, C., Stürmer, T., Weber, D. J., Juliano, J. J., & Perfect, J. R. (2013). Approaches to Antifungal Therapies and Their Effectiveness among Patients with Cryptococcosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01800-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.